Bayer HealthCare (OTCPK:BAYRY) has received orphan drug designation for its use of human monoclonal IgG2 antibody against tissue factor pathway inhibitor, for the treatment of Hemophilia B.
The company had received a similar designation in March for using the approach to treat Hemophilia A.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.